Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00496301
Status:
COMPLETED
Last Update Posted:
2009-01-14
First Post:
2007-07-03
Brief Title:
Clinical Trial on the Mixture of G C and S in Treatment of Patients With RCC
Sponsor:
Spanish Oncology Genito-Urinary Group
Organization:
Spanish Oncology Genito-Urinary Group
Study Overview
Official Title:
Phase II Clinical Trial Non-Randomized Multicentre on the Combination of Gemcitabine Capecitabine and Sorafenib Bay 43-9006 in Treatment of Patients With Unresectable andor Metastatic Renal Cell Carcinoma RCC
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SOGUG-02-06
Brief Summary:
Main Objective
To evaluate progression-free survival in patients with unresectable renal cell carcinoma RCC treated with a combination of gemcitabine capecitabine and sorafenib
To evaluate progression-free survival in patients with unresectable renal cell carcinoma RCC treated with a combination of gemcitabine capecitabine and sorafenib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None